These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25389924)

  • 21. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor.
    Nanno Y; Matsumoto I; Zen Y; Otani K; Uemura J; Toyama H; Asari S; Goto T; Ajiki T; Okano K; Suzuki Y; Takeyama Y; Fukumoto T; Ku Y
    Ann Surg Oncol; 2017 Apr; 24(4):1127-1133. PubMed ID: 27822631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central pancreatectomy: single-center experience of 50 cases.
    Adham M; Giunippero A; Hervieu V; Courbière M; Partensky C
    Arch Surg; 2008 Feb; 143(2):175-80; discussion 180-1. PubMed ID: 18283143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
    Mirkin KA; Hollenbeak CS; Wong J
    J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors.
    Xu SS; Li H; Li TJ; Li S; Xia HY; Long J; Wu CT; Wang WQ; Zhang WH; Gao HL; Han X; Ye LY; Lin X; Xu HX; Yu XJ; Liu L
    Front Immunol; 2021; 12():577517. PubMed ID: 34084158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
    Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
    Teh SH; Deveney C; Sheppard BC
    Am J Surg; 2007 May; 193(5):610-3; discussion 613. PubMed ID: 17434366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
    Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
    World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors.
    Ge W; Zhou D; Xu S; Wang W; Zheng S
    Int J Surg; 2017 Mar; 39():127-134. PubMed ID: 28137555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection.
    Arai T; Kobayashi A; Fujinaga Y; Yokoyama T; Shimizu A; Motoyama H; Kitagawa N; Notake T; Shirota T; Fukushima K; Masuo H; Kadoya M; Miyagawa S
    Pancreatology; 2016; 16(3):397-402. PubMed ID: 26850565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study.
    Regenet N; Carrere N; Boulanger G; de Calan L; Humeau M; Arnault V; Kraimps JL; Mathonnet M; Pessaux P; Donatini G; Venara A; Christou N; Bachelier P; Hamy A; Mirallié E
    Surgery; 2016 Mar; 159(3):901-7. PubMed ID: 26590096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer.
    Kurahara H; Takao S; Kuwahata T; Nagai T; Ding Q; Maeda K; Shinchi H; Mataki Y; Maemura K; Matsuyama T; Natsugoe S
    Ann Surg Oncol; 2012 Jul; 19(7):2264-71. PubMed ID: 22350599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history and malignant risk factors of solid pseudopapillary tumors of the pancreas.
    Park JK; Cho EJ; Ryu JK; Kim YT; Yoon YB
    Postgrad Med; 2013 Mar; 125(2):92-9. PubMed ID: 23816775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Nell S; Borel Rinkes IHM; Verkooijen HM; Bonsing BA; van Eijck CH; van Goor H; de Kleine RHJ; Kazemier G; Nieveen van Dijkum EJ; Dejong CHC; Valk GD; Vriens MR;
    Ann Surg; 2018 Feb; 267(2):352-356. PubMed ID: 27811505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical presentation and outcome of nonfunctional pancreatic neuroendocrine tumors in a modern cohort.
    Watley DC; Ly QP; Talmon G; Are C; Sasson AR
    Am J Surg; 2015 Dec; 210(6):1192-5; discussion 1195-6. PubMed ID: 26674063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parenchyma-sparing surgery for pancreatic endocrine tumors.
    Uccelli F; Gavazzi F; Capretti G; Virdis M; Montorsi M; Zerbi A
    Updates Surg; 2016 Sep; 68(3):313-319. PubMed ID: 27709476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.